Roche Holding AG Stock News

Roche's (RHHBY) performance in the first half of 2023 was ordinary as COVID-19-test sales continue to decline and dent the top line.

Roche CEO Thomas Schinecker warns that sections of the U.S. Inflation Reduction Act could stifle the development of new medicines.

Roche said it had abandoned certain drug development projects or acquisitions under consideration because of planned price cuts in best-selling prescription medicines in the United States.

Roche said first-half core operating profit fell 14% as the Swiss drugs and diagnostics maker was hit by a sharp decline in sales of COVID-19 products but the strong launch of a new eye drug mitigated

Swiss pharmaceutical group Roche said on Monday it had entered into a partnership with U.S. biopharmaceutical company Alnylam to co-develop and co-commercialise zilebesiran, a therapy to treat hyperte

Biotech company Roivant Sciences is nearing a deal to sell an experimental drug to treat inflammatory bowel diseases including ulcerative colitis and Crohn's disease to Roche in a deal that could be v

Roivant, started by presidential candidate Vivek Ramaswamy, could seal a deal in coming days

Roche unveiled positive results Thursday for a rival to TG Therapeutics' infusion for multiple sclerosis patients, and TGTX stock crashed.

Central banks will "change the goalposts without really saying so," on monetary policy, according to veteran strategist David Roche.

David Roche, president of Independent Strategy, shares his predictions for central banks' monetary policy and its implications for the global economy. He also weighs in on the outlook for the war in U

Roche's (RHHBY) blood cancer portfolio gets a boost with the EC's approval of Columvi (glofitamab-gxbm) for treating patients with R/R DLBCL.

Roche's (RHHBY) SMA drug Evrysdi maintains its efficacy and safety profile in children with type 1 SMA after four years of treatment.

Europe is a relevant place for investment due to its role as one of the world's leading economic areas. Europe is home to many well-established multinational companies. Major European stock indices ha

Juha Anjala, co-head of EMEA health-care investment banking at JPMorgan, discusses government support for investment in life sciences, as well as innovation in the sector.

Roche's (RHHBY) blood cancer portfolio gets a boost with the approval of Columvi (glofitamab-gxbm) for treating patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).